Document Detail


AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations.
MedLine Citation:
PMID:  19898425     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The biological behavior of chronic lymphocytic leukemia and small lymphocytic lymphoma is unpredictable. Nonetheless, non-mutated IgV(H) gene rearrangement, ATM (11q22-23) and p53 (17p13) deletion are recognized as unfavorable prognosticators in chronic lymphocytic leukemia. The mRNA expression of activation-induced cytidine deaminase (AID), an enzyme indispensable for somatic hypermutation processes, was claimed to be predictive of non-mutated chronic lymphocytic leukemia cells in blood. Here, we evaluated AID protein expression compared with known molecular and immunohistochemical prognostic indicators in 71 chronic lymphocytic leukemia/small lymphocytic lymphoma patients using a tissue microarray approach. We found AID heterogeneously expressed in tumor cells as shown by colocalization analysis for CD5 and CD23. Ki-67 positive paraimmunoblasts of the proliferation centers displayed the highest expression. This observation is reflected by a significant association of AID positivity with a high proliferation rate (P=0.012). ATM deletion was detected in 10% (6/63) of patients and p53 deletion in 19% (13/67) of patients. Moreover, both ATM (P=0.002) and p53 deletion (P=0.004) were significantly associated with AID. IgV(H) gene mutation was seen in 45% (27/60) of patients. Twenty-five percent (17/69) of patients with AID-positive chronic lymphocytic leukemia/small lymphocytic lymphoma displayed a shorter survival than AID-negative chronic lymphocytic leukemia/small lymphocytic lymphoma patients (61 vs 130 months, P=0.001). Although there was a trend, we could not show an association with the IgV(H) gene mutation status. Taken together, our study shows that AID expression is an indicator of an unfavorable prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma patients, although it is not a surrogate marker for the IgV(H) status. Furthermore, the microenvironment of proliferation centers seems to influence AID regulation and might be an initiating factor in its transformation.
Authors:
Mona Leuenberger; Simona Frigerio; Peter J Wild; Franziska Noetzli; Dimitri Korol; Dieter R Zimmermann; Carole Gengler; Nicole M Probst-Hensch; Holger Moch; Marianne Tinguely
Related Documents :
8308315 - Septicaemia in patients with and without aids at westminster hospital, london.
6320505 - Retinal manifestations of the acquired immune deficiency syndrome (aids): cytomegalovir...
8463645 - Brain biopsy in indiana aids patients.
2384685 - Isolation of protomonas extorquens (the 'red phantom') from a patient with aids.
2814535 - Work stress and mental distress.
17364385 - Putting on a brave face: the experiences of women living with hiv and aids in informal ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-11-06
Journal Detail:
Title:  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc     Volume:  23     ISSN:  1530-0285     ISO Abbreviation:  Mod. Pathol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-03     Completed Date:  2010-04-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8806605     Medline TA:  Mod Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  177-86     Citation Subset:  IM    
Affiliation:
Department of Pathology, Institute of Surgical Pathology, University Hospital, CH-8091Zurich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Cytidine Deaminase / biosynthesis*
DNA Mutational Analysis
Female
Gene Rearrangement
Genes, Immunoglobulin / genetics
Humans
Immunoglobulin Heavy Chains / genetics
Immunoglobulin Variable Region / genetics
Immunohistochemistry
In Situ Hybridization, Fluorescence
Kaplan-Meiers Estimate
Leukemia, Lymphocytic, Chronic, B-Cell / enzymology*,  genetics*,  mortality
Male
Middle Aged
Mutation
Prognosis
Tissue Array Analysis
Tumor Markers, Biological / analysis*
Chemical
Reg. No./Substance:
0/Immunoglobulin Heavy Chains; 0/Immunoglobulin Variable Region; 0/Tumor Markers, Biological; EC 3.5.4.-/AICDA (activation-induced cytidine deaminase); EC 3.5.4.5/Cytidine Deaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Next Document:  Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter pro...